Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells
- 1 March 2021
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 206 (7), 1540-1548
- https://doi.org/10.4049/jimmunol.1900656
Abstract
IL-17A and IL-22 derived from Th17 cells play a significant role in mucosal immunity and inflammation. TGF-β and IL-6 promote Th17 differentiation; however, these cytokines have multiple targets. The identification and screening of additional molecules that regulate IL-17A and IL-22 responses in certain inflammatory conditions is of great clinical significance. In this study, we show that CDDO-Im, a specific Nrf2 activator, promotes IL-17A and IL-22 responses in murine Th17 cells. In contrast, CDDO-Im inhibits IL-17A response in multiple sclerosis patient-derived PBMCs. However, Nrf2 specifically regulates IL-22 response in vivo. Nrf2 acts through the regulation of antioxidant response element (ARE) binding motifs in target genes to induce or repress transcription. Promoter analysis revealed that Il17a, Rorc, and Ahr genes have several ARE motifs. We showed that Nrf2 bound to ARE repressor (ARE-R2) of Rorc and inhibited Rorc-dependent IL-17A transactivation. The luciferase reporter assay data showed that CDDO-Im regulated Ahr promoter activity. Chromatin immunoprecipitation quantitative PCR data showed that Nrf2 bound to ARE of AhR. Finally, we confirmed that the CDDO-Im–mediated induction of IL-22 production in CD4+ T cells was abrogated in CD4-specific Ahr knockout mice (AhrCD4). CH-223191, a specific AhR antagonist, inhibits CDDO-Im–induced IL-22 production in CD4+ T cells, which further confirmed the AhR-dependent regulation. Collectively, our data showed that Nrf2 via AhR pathways regulated IL-22 response in CD4+ T cells.Keywords
Funding Information
- Crohn’s and Colitis Foundation (476637)
- National Multiple Sclerosis Society (PP-1709-29192)
- National Institues of Health/National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK121798-01, R01DK118568)
- Division of Intramural Research/National Institute of Allergy and Infectious Diseases (R21 AI149257)
- Wellcome Trust/Department of Biotechnology India Alliance (IA/I/12/1/500524)
This publication has 62 references indexed in Scilit:
- Small molecule inhibitors of RORγt: Targeting Th17 cells and other applicationsEuropean Journal of Immunology, 2012
- The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid CellsImmunity, 2012
- Th17 Cells Mediate Clade-Specific, Serotype-Independent Mucosal ImmunityImmunity, 2011
- Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitisScientific Reports, 2011
- AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of NotchNature Immunology, 2011
- Mechanisms of neuronal dysfunction and degeneration in multiple sclerosisProgress in Neurobiology, 2011
- CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) ReceptorToxicological Sciences, 2010
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+regulatory T cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- IL-22 mediates mucosal host defense against Gram-negative bacterial pneumoniaNature Medicine, 2008
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006